 |
0 Companies | 0 Products |
|
|
0 Products | |
0 Diseases | |
0 Trials |  |
0 News |  |
| «12 |
- | Journal: Expression of Cripto-1 in the placenta and its role in placenta accreta and placenta previa. (Pubmed Central) - Jan 11, 2020
Placental Cripto-1 is involved in the regulation of placental tissue invasion. Additionally, excessive placental growth or penetration into the myometrium are likely to be involved in the development of placenta increta.
- Origin of somatic transformation in germ cell tumor of testis (TGCT): Role of differentiation versus dedifferentiation in a mature teratoma. (Poster Board E9) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_1157;
Presence of stem cells embedded within mature teratomas and capable of differentiation into separate ontogenetic lineages could account for the origin of somatic transformation in TGCT. Research Funding: Patient Donation
- Origin of somatic transformation in germ cell tumor of testis (TGCT): Role of differentiation versus dedifferentiation in a mature teratoma. (Poster Board E9) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_875;
Presence of stem cells embedded within mature teratomas and capable of differentiation into separate ontogenetic lineages could account for the origin of somatic transformation in TGCT. Research Funding: Patient Donation
- Origin of germ cell tumors: somatic transformation and the presence of cancer stem-like cells in teratoma () - Nov 17, 2019 - Abstract #SUO2019SUO_145;
In addition, we have begun to identify cancer stem-like cells within mature teratoma, suggesting a new hypothesis for predicting teratoma behavior and somatic transformation. By demonstrating that metastatic teratomas and their corresponding somatic transformations had similar if not identical genetic profiles, we hypothesize they have a common clonal origin and question the theory of acquiring specific genetic mutations, which lead to dedifferentiation of teratomas during somatic transformation.
- | Journal: An Intelligent Neural Stem Cell Delivery System for Neurodegenerative Diseases Treatment. (Pubmed Central) - Nov 2, 2019
More interesting is the fact that neural stem cell differentiation can be conducted in astrocyte-differentiation medium without other treatments. In addition, the system can be adjusted according to the different parameters of transplanted stem cells and can expand on the clinical application of stem cells in the treatment of this neurological disorder.
- | Biomarker, Journal: Cripto 1, a potential biomarker for oral squamous cell carcinoma. (Pubmed Central) - Oct 28, 2019
In addition, the system can be adjusted according to the different parameters of transplanted stem cells and can expand on the clinical application of stem cells in the treatment of this neurological disorder. No abstract available
- | doxorubicin hydrochloride / generics
Journal: CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. (Pubmed Central) - Oct 24, 2019
High level CRIPTO expression in xenograft models was associated with resistance to sorafenib, which could be modulated using a CRIPTO pathway inhibitor in ex vivo tumour slices. Our data suggest that a subgroup of CRIPTO-expressing HCC patients may benefit from a combinatorial treatment scheme and sorafenib resistance may be circumvented by inhibition of the CRIPTO pathway.
- | Preclinical, Journal, Cancer stem cells: Cripto-1 plasmid DNA vaccination targets metastasis and cancer stem cells in murine mammary carcinoma. (Pubmed Central) - Oct 24, 2019
Our data indicate that vaccination against Cripto-1 results in a protective immune response against mCr-1 expressing and metastasizing cells. Targeting Cripto-1 by vaccination has promise as an immunotherapy for treatment of metastatic breast cancer.
- | Journal: Identification of myosin II as a cripto binding protein and regulator of cripto function in stem cells and tissue regeneration. (Pubmed Central) - Oct 8, 2019
Taken together, our data present a novel role for myosin II function in regulating subcellular Cripto localization and function in stem cells and an important regulatory mechanism of tissue regeneration. Importantly, these insights may further the development of context-dependent Cripto agonists and antagonists for therapeutic benefit.
- Establishing an in Vitro Model of Hand Osteoarthritis by Generating Induced Pluripotent Stem Cells (iPSc) That Carry Single Nucleotide Polymorphisms Associated with Hand Osteoarthritis Risk (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3190;
The presence of sequence variants within the studied genes was maintained after fibroblast reprogramming. The generated iPSc-lines showed differences in their chondrogenic differentiation capacity, demonstrating their usefulness to model hOA in vitro, and to deeper study the role of these genetic variants in the pathogenesis of hOA.
- Targeting nodal and cripto-1 onco-fetal proteins using bispecific antibody fragments () - Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_221;
This optimized Fab-FITC conjugation reaction confirms the yield of more than 90% and its purity and identity are confirmed by ESI TOF Mass spectrometry. Using the same concept, the Fab of anti-Nodal 3D1 and the Fab of anti-Cripto-1 1B4 molecules will be dimerized to generate the bispecific antibody Fab2 that will be finally employed as the dual anti-Nodal and anti-Cripto-1 theranostic agent.
- | Clinical, Journal: Isolation and identification of chemotherapy-enriched sphere-forming cells from a patient with gastric cancer. (Pubmed Central) - Oct 2, 2019
Thus, these cells have all the characteristics of stationary and migratory CSCs, including tumorigenicity, self-renewal, pluripotency, invasion and metastasis. Taken together, targeting chemotherapy-enriched CSCs as chemo-resistance cells observed in GC patients can provide more effective therapeutic strategies compared to untreated patients.
- Predictive serum markers in immunotherapy (A6) - Sep 30, 2019 - Abstract #DGHO2019DGHO_708;
Although validation in a higher number of patients is required, these findings might provide a feasible opportunity to identify patients who show a response to immune checkpoint inhibition. Furthermore, in-vitro and in-vivo studies are indispensable to further characterize the functional impact of these biomarkers.
- | Journal: Soluble Cripto-1 induces accumulation of supernumerary centrosomes and formation of aberrant mitoses in human embryonic stem cells. (Pubmed Central) - Sep 20, 2019
Linking the secretory phenotype of hESC to the centrosomal metabolism may help to develop better strategies for propagation of stable and safe bioindustrial and clinical grade cultures of hESC. From a broader point of view, it may lead to unravelling Cripto-1 as micro-environmental factor contributing to adverse cell behaviors in vivo.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway. (Pubmed Central) - Sep 11, 2019
...Cripto-1 was upregulated in the sorafenib-resistant clones derived from HCC cell lines and patient-derived xenograft that we previously developed, suggesting an association between Cripto-1 and stemness...Taken together, Cripto-1 binds to FZD7/LRP6 and DVL3, stabilizes DVL3 expression and activates the Wnt/β-catenin signaling cascade to confer stemness in HCC. Our study findings substantiated the role of Cripto-1 in determining stemness phenotypes of HCC and mechanistically in modulating the Wnt/β-catenin signaling cascade, one of the most frequently deregulated pathways in liver cancer.
- | Biomarker, Clinical, Journal: Overexpression levels of cripto-1 predict poor prognosis in patients with prostate cancer following radical prostatectomy. (Pubmed Central) - Aug 29, 2019
Furthermore, multivariate statistical analysis demonstrated that overexpression of CR-1 may be a novel predictor for prognosis of patients with PCa. Accordingly, the present study considered CR-1 to be a valuable predictor of poor prognosis and progression in PCa, and a potential therapeutic target for patients with PCa.
- | Journal, IO Biomarker: Cripto-1 overexpression in U87 glioblastoma cells activates MAPK, focal adhesion and ErbB pathways. (Pubmed Central) - Aug 29, 2019
Angiogenesis could be mediated by Cripto-1 by activating c-Jun (Ser63) through EGFR (Ser1070)/Her2 (Tyr877) of the ErbB pathway. To conclude, the present study has augmented and enriched our current knowledge on the crucial roles that Cripto-1 may play in controlling different cellular mechanisms in GBM cells.
- | Journal: DNA methylation profiling as a tool for testicular germ cell tumors subtyping. (Pubmed Central) - Aug 1, 2019
Different combinations of five genes' promoter methylation levels discriminate among TGCT subtypes. Methylation patterns may also assist in identification of more clinically aggressive tumors.
- | Biomarker, Journal: Targeting Nodal and Cripto-1: perspectives inside dual potential theranostic cancer biomarkers. (Pubmed Central) - Jul 21, 2019
Methylation patterns may also assist in identification of more clinically aggressive tumors. Overall, Nodal and Cripto-1 represent two innovative and effective biomarkers for developing potential theranostic anti-tumor agents that target normal as well as CSC subpopulations and overcome both pharmacological resistance and tumor relapse.
- | Journal: Glucocorticoid receptor-dependent induction of cripto-1 (one-eyed pinhead) inhibits zebrafish caudal fin regeneration. (Pubmed Central) - Jun 30, 2019
Retinoic acid exposure prevented increased cripto-1 expression and permitted regeneration in the presence of BDP. We demonstrated that BDP exposure increased cripto-1 expression in mouse embryonic stem cells and that regulation of cripto-1 by GCs is conserved in mammals.
- | Preclinical, Journal: Variation in primary and culture-expanded cells derived from connective tissue progenitors in human bone marrow space, bone trabecular surface and adipose tissue. (Pubmed Central) - May 22, 2019
Other markers are more likely to discriminate differences between cell populations in biological performance. Understanding the underlying reasons for variation in the concentration, prevalence, marker expression and biological potential of CTPs between patients and source tissues and determining the means of managing this variation will contribute to the rational development of cell-based clinical diagnostics and targeted cell-based therapies.
- | Biomarker, Journal: High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. (Pubmed Central) - Feb 6, 2019
High CR-1 expression is correlated with poor prognosis in NSCLC with low tumor burden and may be used to select high-risk patients for adjuvant chemotherapy in early NSCLC. Moreover, low miR-205 expression likely related to high CR-1 expression could be a prognostic marker for patients with NSCLC.